HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS British Journal of Psychiatry Advances in Psychiatric Treatment All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Yorston, G. Articles by Pinney, A. Search for Related Content PubMed Articles by Yorston, G. Articles by Pinney, A.

Chlorpromazine equivalents and percentage of British National Formulary maximum recommended dose in patients receiving high-dose antipsychotics

Udston Hospital, Farm Road, Hamilton ML3 9LA

AIMS AND METHOD

The study compared two methods of identifying patients prescribed high doses of antipsychotic medication among in-patients and out-patients in Buckinghamshire. High doses were defined as those in excess of 1000 mg chlorpromazine equivalents (CPZE) per day or more than 100% of the maximum recommended dose in the British National Formulary (BNF).

RESULTS

A total of 258 patients were identified as being prescribed antipsychotics, 30 of whom received high doses. There was 93% concordance between the two methods for identifying these patients. Nine of the 12 patients who had been prescribed high potency (> 1000 mg CPZE/day) but low toxicity (> 100% BNF maximum) therapy were receiving flupenthixol decanoate.

A group of six high-risk patients were identified who had been prescribed lower potency drugs at supra-maximal doses.

CLINICAL IMPLICATIONS

Expressing total antipsychotic dose as a percentage of the BNF maximum is easy to understand and calculate. It helps to ensure patients at risk of antipsychotic toxicity are easily identified to ensure monitoring guidelines can be followed.

This article has been cited by other articles:

				A. Connolly and D. Taylor Ethnicity and quality of antipsychotic prescribing among in-patients in south London The British Journal of Psychiatry, August 1, 2008; 193(2): 161 - 162. [Abstract] [Full Text] [PDF]

				G. B. K. Hung and H. K. Cheung A survey of in-patient and out-patient antipsychotic prescriptions in Hong Kong Psychiatr. Bull., March 1, 2008; 32(3): 103 - 105. [Abstract] [Full Text] [PDF]

				A. Connolly, P. Rogers, and D. Taylor Antipsychotic prescribing quality and ethnicity -- a study of hospitalized patients in south east London J Psychopharmacol, March 1, 2007; 21(2): 191 - 197. [Abstract] [PDF]

				C. Haw and J. Stubbs Combined antipsychotics for 'difficult-to-manage' and forensic patients with schizophrenia: reasons for prescribing and perceived benefits Psychiatr. Bull., December 1, 2003; 27(12): 449 - 452. [Abstract] [Full Text] [PDF]

				F. Hynes Real-life prescribing Psychiatr. Bull., October 1, 2003; 27(10): 394 - 394. [Full Text] [PDF]

				M. Harrington, P. Lelliott, C. Paton, C. Okocha, R. Duffett, and T. Sensky The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK Psychiatr. Bull., November 1, 2002; 26(11): 414 - 418. [Abstract] [Full Text] [PDF]